Nirav S. Jhaveri was named Chief Financial Officer of Longeveron Inc., effective August 17, 2026. As of November 6, 2026, Longeveron Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 5, 2026 to October 14, 2026, naming 2 appointments and 1 departure (Form 8-K, August 19, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Longeveron Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-14
- · In / out: In · Person: Nirav S. Jhaveri · Role: Chief Financial Officer · Effective: 2026-08-17 · 8-K, 2026-08-19
- · In / out: In · Person: Marie Washburn · Role: Chief Financial Officer · Effective: 2026-07-13 · 8-K, 2026-07-06
- · In / out: Out · Person: Lisa Locklear · Role: Chief Financial Officer · Effective: 2026-07-10 · 8-K, 2026-06-05
Longeveron Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-05 to 2026-10-14. They name 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Longeveron Inc. files it.
Also on the record for Longeveron Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by Integrated Core Strategies (US) LLC | — | 5%+ stakes | Source |
| September 10, 2026 | Stake report, Schedule 13G, by Logos Global Management LP | 6.3% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 9% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13G, by Integrated Core Strategies (US) LLC | 5.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 5.9% of the class | 5%+ stakes | Source |
| March 25, 2026 | Form D, private offering | $15.89M sold | Form D page | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Lincoln Alternative Strategies LLC | — | 5%+ stakes | Source |
| August 27, 2025 | Stake report, Schedule 13G, by Lincoln Alternative Strategies LLC | 6.09% of the class | 5%+ stakes | Source |
| August 15, 2025 | Stake report, Schedule 13G, by Mitchell P. Kopin | 9.99% of the class | 5%+ stakes | Source |
| September 13, 2021 | Court case: Malespin v. Longeveron Inc., District Court, S.D. Florida | — | Court records | Source |
Selling to them or working with them? See who runs Longeveron Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Longeveron Inc. and the records around it.
Longeveron Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing Mar 2026
- Who owns it
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Bionano Genomics, Inc. (Sep 2025)
- Logos Global Management LP also filed stake reports on 14 other companies: ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026), Avalo Therapeutics, Inc. (May 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch Longeveron Inc.
Get an email when Longeveron Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Longeveron Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Longeveron Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Longeveron Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-14 | Reported | not named in the filing | 8-K, 2026-10-14 | ||
| 2026-08-19 | In | Chief Financial Officer | 2026-08-17 | 8-K, 2026-08-19 | |
| 2026-07-06 | In | Chief Financial Officer | 2026-07-13 | 8-K, 2026-07-06 | |
| 2026-06-05 | Out | Chief Financial Officer | 2026-07-10 | 8-K, 2026-06-05 |
Who leads Longeveron Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Nirav S. Jhaveri, appointed, effective 2026-08-17 (filed 2026-08-19).
New leaders reset buying decisions — get the Full Report on Longeveron Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Longeveron Inc. (free up to 3)
Find people with the same kind of experience as the Chief Financial Officer at Longeveron Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Longeveron Inc.Every change, in the filing's words
Reported
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026. 1
Appointed: Nirav S. Jhaveri, Chief Financial Officer, effective 2026-08-17
Longeveron Inc. (the "Company") has appointed Nirav S. Jhaveri to serve as Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective August 17, 2026 (the "Effective Date").
- Mr. Jhaveri, age 48, has over 25 years of biopharma and biotech leadership experience across public and private sectors, including experience as the Chief Financial Officer of gene-therapy and biotech companies.
- Mr. Jhaveri most recently served as an independent strategic advisor to select early-stage biotech companies where he advised the companies' Chief Executive Officers on capital markets insights, corporation position, investor targeting, and fundraising activities.
- Prior to that time, Mr. Jhaveri served as Chief Financial Officer of Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company, from February 2024 to June 2025, Insilico Medicine, a global artificial intelligence-driven biotech company from 2021 to 2023, and Journey Medical Corporation (Nasdaq: DERM, although pre-IPO during Mr. Jhaveri's tenure), a commercial-stage pharmaceutical company from 2020 to 2021.
- Mr. Jhaveri received his B.A. from University of Pennsylvania and his MBA from New York University.
- Marie Washburn, who has been serving as Chief Financial Officer of the Company will remain with the Company in her prior role of Vice President and Corporate Controller.
Appointed: Marie Washburn, Chief Financial Officer, effective 2026-07-13
In connection with Ms. Locklear's departure, on June 30, 2026, the Company appointed Marie Washburn to the Company's executive leadership team in the role of Senior Vice President and Chief Financial Officer ("CFO"), principal financial officer and principal accounting officer of the Company, effective July 13, 2026 (the "Effective Date").
- (c) As previously disclosed, on June 1, 2026, Lisa Locklear, Chief Financial Officer of Longeveron Inc. (the "Company"), provided notice to the Company of her decision to step down as Chief Financial Officer of the Company, effective July 10, 2026.
- Ms. Washburn, age 51, has served as the Company's Vice President and Corporate Controller since November 2025.
- Ms. Washburn received a B.S. in Business Administration from Bryant University in 1997.
- In connection with her appointment, the Company and Ms. Washburn entered into a Letter Agreement (the "Agreement"), effective as of the Effective Date.
- Pursuant to the Agreement, Ms. Washburn will be entitled to receive a base salary of $340,000 per year, and is eligible to participate in the Company's performance-based annual cash incentive plan, with an award target equal to forty-five percent (45%) of her base salary, as well as short and long-term equity incentive awards pursuant to the terms of the Company's 2021 Incentive Award Plan, as amended and/or amended or restated to date (or any successor plan thereto).
- As of the Effective Date, Ms. Washburn will receive an equity award of 130,000 time-based vesting Restricted Stock Units.
- Under the Agreement, Ms. Washburn will also be eligible for participation in standard Company employee benefit programs as well as termination and severance benefits.
Departing: Lisa Locklear, Chief Financial Officer, effective 2026-07-10
On June 1, 2026, Ms. Lisa Locklear informed management of Longeveron Inc. (the "Company") of her decision to step down as Chief Financial Officer, to become effective July 10, 2026.
- Ms. Locklear will continue to work with the Company's current controller, Marie Washburn, who the Company anticipates will be elevated into the CFO role upon Ms. Locklear's departure (pending final contract).
Longeveron Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Longeveron Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.